



Clinical trial results:

A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion

Summary

EudraCT number	2015-005576-22
Trial protocol	IT
Global end of trial date	09 July 2024

Results information

Result version number	v2 (current)
This version publication date	18 January 2026
First version publication date	25 July 2025
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	201501
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03370172
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Takeda
Sponsor organisation address	95 Hayden Avenue, Lexington, MA, United States, 02421
Public contact	Study Director, Takeda, TrialDisclosures@takeda.com
Scientific contact	Study Director, Takeda, TrialDisclosures@takeda.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 July 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	09 July 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial was to evaluate the safety of a single intravenous (IV) infusion of BAX 888 in 2 dose cohorts.

Protection of trial subjects:

Participant signed an informed consent form (ICF) before participating in the study.

Background therapy:

NA

Evidence for comparator:

NA

Actual start date of recruitment	27 February 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	Spain: 3
Worldwide total number of subjects	4
EEA total number of subjects	4

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 4 participants took part in the study globally from 27 February 2018 to 09 July 2024.

Pre-assignment

Screening details:

Participants with severe Hemophilia A participated in the study to receive BAX 888.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
------------------------------	----

Arm title	Cohort 1: BAX 888 2.0*10 ¹² cp/kg
------------------	--

Arm description:

Cohort 1 participants received a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10¹² capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).

Arm type	Experimental
Investigational medicinal product name	BAX 888
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Cohort 1 participants received a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10¹² capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).

Arm title	Cohort 2: BAX 888 6.0*10 ¹² cp/kg
------------------	--

Arm description:

Cohort 2 participants received a single peripheral IV infusion of BAX 888 at a dose of 6.0*10¹² cp/kg on the day of dosing (Day 0).

Arm type	Experimental
Investigational medicinal product name	BAX 888
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Cohort 2 participants received a single peripheral IV infusion of BAX 888 at a dose of 6.0*10¹² cp/kg on the day of dosing (Day 0).

Number of subjects in period 1	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg
Started	2	2
Completed	2	1
Not completed	0	1
Consent withdrawn by subject	-	1

Baseline characteristics

Reporting groups

Reporting group title	Cohort 1: BAX 888 2.0*10 ¹² cp/kg
Reporting group description: Cohort 1 participants received a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10 ¹² capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).	
Reporting group title	Cohort 2: BAX 888 6.0*10 ¹² cp/kg
Reporting group description: Cohort 2 participants received a single peripheral IV infusion of BAX 888 at a dose of 6.0*10 ¹² cp/kg on the day of dosing (Day 0).	

Reporting group values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg	Total
Number of subjects	2	2	4
Age Categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	29.5 ± 13.44	27.5 ± 3.54	-
Gender categorical Units: Subjects			
Female	0	0	0
Male	2	2	4
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	2	2	4
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	2	2	4
Unknown or Not Reported	0	0	0

End points

End points reporting groups

Reporting group title	Cohort 1: BAX 888 2.0*10 ¹² cp/kg
Reporting group description: Cohort 1 participants received a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10 ¹² capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).	
Reporting group title	Cohort 2: BAX 888 6.0*10 ¹² cp/kg
Reporting group description: Cohort 2 participants received a single peripheral IV infusion of BAX 888 at a dose of 6.0*10 ¹² cp/kg on the day of dosing (Day 0).	

Primary: Number of Participants With BAX 888-Related Adverse Events (AEs)

End point title	Number of Participants With BAX 888-Related Adverse Events (AEs) ^[1]
End point description: An AE is defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. A Serious adverse event (SAE) is an AE resulting in any of the following outcomes: death; life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. AEs include both serious and non-serious adverse events including development of FVIII inhibitory antibodies, clinically significant changes in standard laboratory parameters, physical exam, and vital signs. The Safety Set consisted of all participants who received any amount of investigational product(IP).	
End point type	Primary
End point timeframe: From first dose up to end of the study (approximately 6 years)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analyses were planned for this end point.

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: participants	2	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Clinically Significant Change From Baseline in Circulating Plasma FVIII Antigen Level

End point title	Number of Participants With Clinically Significant Change From Baseline in Circulating Plasma FVIII Antigen Level
End point description: Change from baseline in circulating plasma FVIII antigen (protein) levels were to be assessed and number of participants with clinically significant change as determined by the principal investigator (PI) were reported. The Safety Set consisted of all participants who received any amount of IP.	

End point type	Secondary
End point timeframe:	
Baseline, up to Month 60	

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: participants	2	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Annualized Bleed Rate (ABR)

End point title	Annualized Bleed Rate (ABR)
End point description:	
ABR in comparison to before gene transfer will be assessed. A bleed is defined as subjective or objective evidence of bleeding which may or may not require treatment with FVIII. ABR was calculated as (number of bleeding episodes/observed treatment period in days)*365.25. The Safety Set consisted of all participants who received any amount of IP.	
End point type	Secondary
End point timeframe:	
Up to approximately 6 years 4 months	

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: bleeds per year				
arithmetic mean (standard deviation)	1.0 (± 1.41)	0.5 (± 0.71)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Circulating Plasma FVIII Activity Level

End point title	Change from Baseline in Circulating Plasma FVIII Activity Level
End point description:	
Change from baseline in circulating plasma FVIII activity level, based on one-stage clotting assay was assessed. The Safety Set consisted of all participants who received any amount of IP. Subjects analysed is the number of participants with data available for analysis for this outcome measure. 99999 indicates	

standard deviation (SD) was not estimable for a single participant.

End point type	Secondary
End point timeframe:	
Baseline, up to Month 60	

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	1		
Units: International Units per deciliter(IU/dL)				
arithmetic mean (standard deviation)	11.40 (± 1.131)	248.30 (± 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a Reduction in Consumption of Exogenous FVIII

End point title	Percentage of Participants With a Reduction in Consumption of Exogenous FVIII
-----------------	---

End point description:

The reduction in consumption of exogenous FVIII was assessed by comparing the amount of exogenous FVIII taken at earliest time point available (prior to BAX 888 infusion) with the amount taken at the last post-infusion timepoint available, during the study. Percentage of participants with reduction in consumption of exogenous FVIII are reported. The Safety Set consisted of all participants who received any amount of IP.

End point type	Secondary
End point timeframe:	
Up to approximately 6 years 4 months	

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: percentage of participants				
number (not applicable)	0.0	0.0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Developed Inhibitory Antibodies to FVIII

End point title	Number of Participants Who Developed Inhibitory Antibodies to FVIII
-----------------	---

End point description:

Participants were assessed to check if they developed inhibitory antibodies to FVIII. The Safety Set consisted of all participants who received any amount of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 6 years 4 months

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: participants	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants Who Developed Total Binding Antibodies to FVIII

End point title	Number of Participants Who Developed Total Binding Antibodies to FVIII
-----------------	--

End point description:

Participants were assessed to check if they developed total binding antibodies to FVIII (Immunoglobulin G [IgG], Immunoglobulin M [IgM]). The Safety Set consisted of all participants who received any amount of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 6 years 4 months

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: participants	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Humoral and Cell-Mediated Immune Response to AAV8 and FVIII Proteins

End point title	Number of Participants With Humoral and Cell-Mediated Immune Response to AAV8 and FVIII Proteins
End point description: Humoral(antibody-mediated) & cell-mediated immune response (IR) to adeno-associated virus(AAV8) (vector) & FVIII proteins (Pr),was assessed.Humoral IR:indicated by presence of specific antibodies (Ab).Anti-AAV8 binding Ab,IgG or IgM were measured by enzyme-linked immunosorbent assay(ELISA) method.Neutralizing Ab were measured by a cell-based luminescent assay.Cell-mediated IR:AAV8 & FVIII specific cell mediated immunity was assessed using validated interferon-γ(IFN-γ) enzyme-linked immunosorbent spot(ELISpot) assays.This assay tests human T-cell recall response to the AAV8 & FVIII Pr.These Pr were called antigens for these tests(AAV8 peptide pools 1, 2, 3 & two pooled test antigens(1 & 2) for FVIII).Number of participants who had humoral and/or cell mediated IR to AAV8 & FVIII Pr,are reported by humoral & cell mediated IR categories.Safety Set.'n':number of participants with data available for analysis for the specified categories.9999 indicates no participant available for analysis.	
End point type	Secondary
End point timeframe: Up to approximately 6 years 4 months	

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: participants				
Humoral: Binding Ab to AAV8 IgG Titer (n=2,1)	2	1		
Humoral: Binding Ab to AAV8 IgM Titer (n=0,0)	9999	9999		
Humoral: Neutralising Ab to AAV8 Titer (n=2,1)	2	1		
Cell-Mediated: AAV8 Peptide Pool 1 Mean (n=2,1)	0	1		
Cell-Mediated: AAV8 Peptide Pool 2 Mean (n=2,1)	1	1		
Cell-Mediated: AAV8 Peptide Pool 3 Mean (n=2,1)	1	1		
Cell-Mediated: FVIII Peptide Pool 1 Mean (n=2,1)	0	0		
Cell-Mediated: FVIII Peptide Pool 2 Mean (n=2,1)	1	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Surveillance of AAV8 Genome Shedding

End point title	Surveillance of AAV8 Genome Shedding
End point description: Surveillance of AAV8 genome shedding in blood, saliva, semen, stool and urine until two consecutive negative results were assessed. The Safety Set consisted of all participants who received any amount of IP. The data was collected for each category until 2 consecutive measurements were negative. 'n' is the number of participants with data available for analysis at specified time points. 9999 indicates no	

participant was available for analysis. 99999 indicates SD was estimable for a single participant. 999999 indicates mean and SD were not estimable due to genome concentrations being Below Limit of Detection.

End point type	Secondary
End point timeframe:	
Blood: Day 1, weekly at Clinic Visits between Weeks 1-15, and at Months 4 and 5; Saliva, Semen, and Stool: Day 1 and Week 1; Urine: Day 1 and Weeks 1,2,3	

End point values	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	Cohort 2: BAX 888 6.0*10 ¹² cp/kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: Genome copies per 100 ng of sample				
arithmetic mean (standard deviation)				
Blood: Day 1 (n=0,1)	9999 (± 9999)	3684434.0 (± 99999)		
Blood: Week 1 (n=1,2)	3634.0 (± 99999)	18608.0 (± 664.68)		
Blood: Week 2 (n=2,2)	2076.0 (± 295.57)	10670.0 (± 3900.40)		
Blood: Week 3 (n=2,2)	2069.0 (± 741.05)	9845.0 (± 6488.41)		
Blood: Week 4 (n=1,2)	1098.0 (± 99999)	9033.5 (± 4978.74)		
Blood: Week 5 (n=2,2)	1483.0 (± 1097.43)	7884.0 (± 288.50)		
Blood: Week 6 (n=2,2)	904.0 (± 335.17)	5372.5 (± 441.94)		
Blood: Week 7 (n=2,2)	1004.0 (± 656.20)	6808.0 (± 1121.47)		
Blood: Week 8 (n=2,2)	828.5 (± 267.99)	7384.0 (± 1011.16)		
Blood: Week 9 (n=2,2)	714.5 (± 222.74)	6384.5 (± 195.87)		
Blood: Week 10 (n=2,2)	773.0 (± 9.90)	6144.5 (± 939.74)		
Blood: Week 11 (n=2,2)	755.0 (± 241.83)	3935.0 (± 1547.15)		
Blood: Week 12 (n=2,2)	728.0 (± 130.11)	3893.5 (± 276.48)		
Blood: Week 13 (n=2,2)	654.0 (± 22.63)	3044.5 (± 1191.47)		
Blood: Week 14 (n=2,2)	735.5 (± 82.73)	2856.0 (± 1473.61)		
Blood: Week 15 (n=1,2)	742.0 (± 99999)	2812.0 (± 2083.14)		
Blood: Month 4 (n=2,1)	422.0 (± 192.33)	3066.0 (± 99999)		
Blood: Month 5 (n=0,1)	9999 (± 9999)	210.0 (± 99999)		
Saliva: Day 1 (n=2,2)	935.0 (± 268.70)	2076.5 (± 473.05)		
Saliva: Week 1 (n=0,2)	9999 (± 9999)	352.5 (± 12.02)		
Semen: Day 1 (n=1,2)	55.0 (± 99999)	230.5 (± 188.80)		

Semen: Week 1 (n=0,1)	9999 (± 9999)	194.0 (± 99999)		
Stool: Day 1 (n=0,1)	9999 (± 9999)	5985.0 (± 99999)		
Stool: Week 1 (n=0,2)	9999 (± 9999)	7164.0 (± 7993.14)		
Urine: Day 1 (n=2,2)	999999 (± 999999)	999999 (± 999999)		
Urine: Week 1 (n=2,2)	999999 (± 999999)	999999 (± 999999)		
Urine: Week 2 (n=2,2)	999999 (± 999999)	999999 (± 999999)		
Urine: Week 3 (n=2,2)	999999 (± 999999)	999999 (± 999999)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-cause mortality: Up to approximately 6 years 4 months; SAEs and Other (Non-Serious) AEs: From first dose up to end of the study (approximately 6 years)

Adverse event reporting additional description:

The Safety Set consisted of all participants who received any amount of investigational product.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.0
--------------------	------

Reporting groups

Reporting group title	Cohort 2: BAX 888 6.0*10 ¹² cp/kg
-----------------------	--

Reporting group description:

Cohort 2 participants received a single peripheral IV infusion of BAX 888 at a dose of 6.0*10¹² cp/kg on the day of dosing (Day 0).

Reporting group title	Cohort 1: BAX 888 2.0*10 ¹² cp/kg
-----------------------	--

Reporting group description:

Cohort 1 participants received a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10¹² capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).

Serious adverse events	Cohort 2: BAX 888 6.0*10 ¹² cp/kg	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Metabolism and nutrition disorders			
Hypophosphataemia			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort 2: BAX 888 6.0*10 ¹² cp/kg	Cohort 1: BAX 888 2.0*10 ¹² cp/kg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 2 (100.00%)	2 / 2 (100.00%)	
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 2 (0.00%) 0	
General disorders and administration site conditions Influenza like illness subjects affected / exposed occurrences (all) Asthenia subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 2 0 / 2 (0.00%) 0	0 / 2 (0.00%) 0 1 / 2 (50.00%) 1	
Respiratory, thoracic and mediastinal disorders Rhinorrhoea subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1 1 / 2 (50.00%) 1	1 / 2 (50.00%) 1 0 / 2 (0.00%) 0	
Psychiatric disorders Irritability subjects affected / exposed occurrences (all) Initial insomnia subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1 1 / 2 (50.00%) 1	0 / 2 (0.00%) 0 0 / 2 (0.00%) 0	
Investigations Weight increased subjects affected / exposed occurrences (all) SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1 0 / 2 (0.00%) 0	0 / 2 (0.00%) 0 2 / 2 (100.00%) 2	
Injury, poisoning and procedural complications Ligament sprain subjects affected / exposed occurrences (all) Fall	1 / 2 (50.00%) 1	0 / 2 (0.00%) 0	

subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 2 (0.00%) 0	
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 2 (0.00%) 0	
Nervous system disorders Headache subjects affected / exposed occurrences (all) Migraine subjects affected / exposed occurrences (all) Paraesthesia subjects affected / exposed occurrences (all) Somnolence subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 6 1 / 2 (50.00%) 3 0 / 2 (0.00%) 0 1 / 2 (50.00%) 1	1 / 2 (50.00%) 2 0 / 2 (0.00%) 0 1 / 2 (50.00%) 1 0 / 2 (0.00%) 0	
Eye disorders Dry eye subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 2 (0.00%) 0	
Gastrointestinal disorders Tongue geographic subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1 0 / 2 (0.00%) 0 1 / 2 (50.00%) 2	0 / 2 (0.00%) 0 1 / 2 (50.00%) 1 0 / 2 (0.00%) 0	
Hepatobiliary disorders Hypertransaminaemia subjects affected / exposed occurrences (all)	2 / 2 (100.00%) 2	2 / 2 (100.00%) 3	

Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Erythema			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Night sweats			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Rash			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	2	0	
Dermatitis acneiform			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Dermatosis			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Musculoskeletal chest pain			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Back pain			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Arthritis			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	2	
Arthralgia			
subjects affected / exposed	1 / 2 (50.00%)	1 / 2 (50.00%)	
occurrences (all)	1	1	
Musculoskeletal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Pain in extremity			

subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Synovitis			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Tendon disorder			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 2 (50.00%)	1 / 2 (50.00%)	
occurrences (all)	1	1	
Rhinitis			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Gastroenteritis			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Nasopharyngitis			
subjects affected / exposed	0 / 2 (0.00%)	2 / 2 (100.00%)	
occurrences (all)	0	2	
Pharyngitis			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Urinary tract infection			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Upper respiratory tract infection			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Increased appetite			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Hypophosphataemia			

subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	3	0	
Hyperphagia			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Vitamin D deficiency			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 March 2017	The following changes were made as per Amendment 1: 1. Updated timelines and added an extension trial timeline. 2. Increased target improvement in FVIII from 5% to 20%. 3. Expanded the description of the benefits and the risks. 4. Increased target proportion of participants with improvement in FVII from 50% to 60%. 5. Simplified the original 3 cohort, parallel group design to allow 2 cohorts in sequence.
24 January 2018	The following changes were made as per Amendment 4: 1. Added Months 24 and 36 to Hemophilia Joint Health Score assessment. 2. Added collection of untoward events in e-diary. 3. Extended exclusion criterion relating to known hypersensitivity to prednisolone or prednisone to also include hypersensitivity to any of the excipients.
16 August 2018	The following changes were made as per Amendment 5: 1. Eliminated Exclusion Criterion 5: "Positive AAV8 specific T-cell ELISPOTs for any AAV8 peptide pools" and deletion of optional assessment: CMI response to AAV8 and FVIII transgene products (if Screening 2 was longer than 4 weeks from Screening 1). 2. Deleted nonclinical Dose Response Study and Toxicity Study, and added reference to investigator's Brochure. 3. Deleted administration of 10% of the BAX 888 with "a syringe driver pump" to maintain consistency with BAX 888 Study Pharmacy Manual. 4. Added language to allow additional analyses on efficacy and safety data at trial milestones.
03 May 2019	The following changes were made as per Amendment 6: 1. Added Cohort 3. 2. Deleted dose escalation triggered by Week 4 FVIII activity levels from Cohort 2. 3. Updated recruitment period. 4. Updated targeted accrual to reflect addition of Cohort 3. 5. Deleted the Short (Accelerated) Tapering Regimen for corticosteroids. 6. Updated immunosuppression with prophylactic corticosteroids.
12 March 2020	The following changes were made as per Amendment 7: 1. Specified the minimum data on which the DMC recommendation will be based. 2. Updated cohort expansion rules for Cohort 2. 3. Updated cohort expansion and rules for dose escalation to Cohort 2 and Cohort 3 doses. 4. Lowered the dose for Cohort 3 from 1.8×10^{13} cp/kg to 1.2×10^{13} cp/kg. 5. Deleted Inclusion Criterion 4 (normal prothrombin time) and instead inserted new Exclusion Criterion 17 to provide upper limit of prothrombin time international normalized ratio. 6. Added AAV2 binding and neutralizing antibodies as exploratory assay.
22 March 2021	The following changes were made as per Amendment 8: 1. Revised Trial Completion Date to Q3 2026. 2. Revised trial duration from 5 years to 8 years. 3. Deleted text regarding an additional 2 years in an extension trial. 4. Added evaluations at Months 36, 48, and 60. 5. Added long-term safety and efficacy evaluations annually at years 4 and 5. 6. Increased overall duration of the trial from 6 to 8 years because trial completion was changed from 3 to 5 years post gene transfer.
10 November 2021	The following changes were made as per Amendment 9: 1. Updated sponsor information and protocol history on the Title Page, Protocol signature page, Section 14.6 Non-compliance With the Protocol, Figure 2 Study Design, and Figure 3 Dose Escalation Schema.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported